T. Björk

发表

Production of alpha-1-antichymotrypsin by PSA-containing cells of human prostate epithelium.

H. Lilja, A. di Sant'Agnese, A. Bjartell, 1993, Urology.

Reproducibility and accuracy of measurements of free and total prostate-specific antigen in serum vs plasma after long-term storage at -20 degrees C.

G. Berglund, J. Hugosson, H. Lilja, 2006, Clinical chemistry.

Treatment costs for advanced prostate cancer using luteinizing hormone-releasing hormone agonists: a solid biodegradable leuprorelin implant versus other formulations.

A. Merseburger, T. Björk, J. Whitehouse, 2015, Journal of comparative effectiveness research.

Rapid exponential elimination of free prostate-specific antigen contrasts the slow, capacity-limited elimination of PSA complexed to alpha 1-antichymotrypsin from serum.

H. Lilja, T. Piironen, K. Pettersson, 1998, Urology.

Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration

T. Tammela, P. Iversen, T. Morris, 2006, BJU international.

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

P. Scardino, A. Vickers, D. Sjoberg, 2013, BMJ : British Medical Journal.

Radioimmunoassay of beta-microseminoprotein, a prostatic-secreted protein present in sera of both men and women.

H. Lilja, P. Fernlund, T. Björk, 1989, Clinical Chemistry.

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

P. Scardino, J. Eastham, G. Berglund, 2008, BMC medicine.

Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years.

Andrew J Vickers, Thomas Björk, Hans Lilja, 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

H. Lilja, J. Schalken, B. Ljungberg, 2001, The Prostate.

Concentrations of ciprofloxacin in serum and prostatic tissue in patients undergoing transurethral resection

A. Forsgren, M. Grabe, T. Björk, 1986, European Journal of Clinical Microbiology.

Prostate specific antigen concentration at age 60 and death or metastasis from prostate cancer: case-control study

P. Scardino, A. Vickers, H. Lilja, 2010, BMJ : British Medical Journal.

Quantitative bone scintigraphy in patients with prostatic carcinoma treated with LH-RH analogues.

G. Sundkvist, T. Björk, B. Lilja, 1996, Scandinavian journal of urology and nephrology.

Controlled trial of a short and a prolonged course with ciprofloxacin in patients undergoing transurethral prostatic surgery

A. Forsgren, M. Grabe, T. Björk, 1987, European Journal of Clinical Microbiology.

Alpha 1-antichymotrypsin production in PSA-producing cells is common in prostate cancer but rare in benign prostatic hyperplasia.

H. Lilja, A. di Sant'Agnese, A. Bjartell, 1994, Urology.

Significance and metabolism of complexed and noncomplexed prostate specific antigen forms, and human glandular kallikrein 2 in clinically localized prostate cancer before and after radical prostatectomy.

A. Haese*, H. Lilja, H. Huland, 1999, The Journal of urology.

Immunohistochemical detection of cysteine‐rich secretory protein 3 in tissue and in serum from men with cancer or benign enlargement of the prostate gland

H. Lilja, L. Kjeldsen, A. Bjartell, 2006, The Prostate.

Serum prostate specific antigen complexed to alpha 1-antichymotrypsin as an indicator of prostate cancer.

O. Nilsson, H. Lilja, A. Christensson, 1993, The Journal of urology.

Dual-label one-step immunoassay for simultaneous measurement of free and total prostate-specific antigen concentrations and ratios in serum.

H. Lilja, T. Piironen, K. Pettersson, 1995, Clinical chemistry.

Long-term prediction of prostate cancer: prostate-specific antigen (PSA) velocity is predictive but does not improve the predictive accuracy of a single PSA measurement 15 years or more before cancer diagnosis in a large, representative, unscreened population.

P. Scardino, J. Eastham, G. Berglund, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: Towards a biologically‐based screening strategy

Andrew J Vickers, Thomas Björk, Hans Lilja, 2007, International journal of cancer.

Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum.

J. Oesterling, H. Lilja, T. Piironen, 2000, The Journal of urology.

Percent-free prostate specific antigen is elevated in men on haemodialysis or peritoneal dialysis treatment.

H. Lilja, A. Christensson, T. Björk, 2003, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

Comparison of analysis of the different prostate-specific antigen forms in serum for detection of clinically localized prostate cancer.

J. Oesterling, H. Lilja, U. Stenman, 1996, Urology.

A novel automated platform for quantifying the extent of skeletal tumour involvement in prostate cancer patients using the Bone Scan Index.

Mattias Ohlsson, Lars Edenbrandt, Karl Sjöstrand, 2012, European urology.

Intra‐individual short‐term variability of prostate‐specific antigen and other kallikrein markers in a serial collection of blood from men under evaluation for prostate cancer

A. Vickers, H. Lilja, A. Christensson, 2011, BJU international.

Phase I safety, pharmacokinetic, and pharmacodynamic trial of ZD1839, a selective oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with five selected solid tumor types.

A. Harris, J. Baselga, M. Ranson, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

P. Scardino, D. Sjoberg, H. Lilja, 2013, BMJ : British Medical Journal.

Secretory Protein 3 inTissue andin SerumFrom MenWithCancerorBenign Enlargement of the ProstateGland

H. Lilja, L. Kjeldsen, V. Gadaleanu, 2006 .

Strategy for detection of prostate cancer based on relation between prostate specific antigen at age 40-55 and long term risk of metastasis: case-control study

P. Scardino, H. Lilja, A. Bjartell, 2013 .

986 HOW SOON CAN WE IDENTIFY MEN AT HIGH RISK FOR PROSTATE CANCER DEATH? AN EARLY SURVEILLANCE STRATEGY FOR PROSTATE CANCER

P. Scardino, A. Vickers, H. Lilja, 2011 .

1202 CAN AN EARLY PSA RULE OUT SUBSEQUENT ADVANCED PROSTATE CANCER? LONG TERM RISK OF ADVANCED CANCER IN MEN WITH LOW PSA LEVELS AT AGE BELOW 50

P. Scardino, A. Vickers, H. Lilja, 2011 .

The prognostic value of different forms of prostate specific antigen and their ratios in patients with prostate cancer

T. Björk, Lilja, Christensson, 1999, BJU international.

Prostate-specific antigen at or before age 50 as a predictor of advanced prostate cancer diagnosed up to 25 years later: A case-control study

P. Scardino, J. Eastham, G. Berglund, 2008, BMC medicine.